Kuromanin

Kuromanin

SCHEMBL409593

OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 2/20 1.00
DPP4 P27487 2/20 1.00
F2 P00734 2/20 0.89
KDM4E B2RXH2 4/20 0.52
GAA P10253 4/20 0.52
AKR1B1 P15121 4/20 0.52
MAPT P10636 3/20 0.52
POLB P06746 2/20 0.52
P4HB P07237 2/20 0.52
EPHX2 P34913 2/20 0.52
ADRA2C P18825 1/20 0.52
NOX4 Q9NPH5 1/20 0.52
CA12 O43570 1/20 0.52
KDM1A O60341 1/20 0.52
SLCO2B1 O94956 1/20 0.52
CA2 P00918 1/20 0.52
ALPL P05186 1/20 0.52
HMGB1 P09429 1/20 0.52
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kuromanin SCHEMBL9234361 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL30548128 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL29349861 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL1101355 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL8818180 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL289710 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL1097555 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL288591 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL1096430 1.00 CD38 (1.00) CD38DPP4F2KDM4EGAA
Kuromanin SCHEMBL440823 0.99 DPP4 (0.98) CD38DPP4F2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724031-A1 EXTRACT OF THE CYBELE VARIETY OF PUNICA GRANATUM, AND USES THEREOF IN COSMETICS GATTEFOSSE SAS (FR) 2026-04-15 EP claimed
WO-2024256768-A1 EXTRACT OF THE CYBELE VARIETY OF PUNICA GRANATUM, AND USES THEREOF IN COSMETICS GATTEFOSSE SAS (FR) 2024-12-19 WO claimed
EP-2785798-B1 ANTHOCYANIN-BASED COLORANT OTERRA AS (DK) 2024-03-13 EP claimed
CN-110133141-B Method for identifying camellia flower color bud mutation variety 中国林业科学研究院亚热带林业研究所 2022-05-27 CN claimed
CN-109651463-B Method for separating cyanidin from red raspberry fruits by high-speed counter-current chromatography 辽宁大学 2022-04-05 CN claimed
US-9884008-B2 Dental cleaning composition JR CHEM, LLC (US) 2018-02-06 US claimed
US-20150182445-A1 DENTAL CLEANING COMPOSITION JR CHEM, LLC (US) 2015-07-02 US claimed
US-20120171128-A1 DENTAL CLEANING COMPOSITION JR CHEM, LLC (US) 2012-07-05 US claimed
US-20100303935-A1 Medicinal Composition MCGINLEY PARTNERS, LLC (US) 2010-12-02 US claimed
US-20090082285-A1 Adiponectin expression promoter SAN-EI GEN F.F.I., INC. (JP) 2009-03-26 US claimed
EP-1443948-B1 PROCESS FOR THE PREPARATION OF ANTHOCYANIN-CONTAINING PRODUCTS MEDPALETT PHARMACEUTICALS AS (NO) 2005-06-29 EP claimed
WO-2005009140-A1 USE OF ANTHOCYANINS IN FISH FOOD BIOCHEM LABORATORIES AS (NO) 2005-02-03 WO claimed
WO-2004096240-A1 ANTHOCYANINS USEFUL FOR THE TREATMENT OF DIABETES, CARDIOVASCULAR DISORDERS AND TO LOWER THE RISK OF ADVERSE EFFECTS OF HORMONE REPLACEMENT THERAPY MEDPALETT PHARMACEUTICALS AS (NO) 2004-11-11 WO claimed
WO-2004087129-A1 COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASE USING BLACK RICE EXTRACT AND ITS THERAPEUTIC USE CELLMICS CO. LTD. (KR) 2004-10-14 WO claimed
EP-1443948-A1 PROCESS FOR THE PREPARATION OF ANTHOCYANIN-CONTAINING PRODUCTS Medpalett Pharmaceuticals AS (NO) 2004-08-11 EP claimed
US-20030091660-A1 Product MEDPALETT PHARMACEUTICALS AS (NO) 2003-05-15 US claimed
WO-2003039569-A1 PROCESS FOR THE PREPARATION OF ANTHOCYANIN-CONTAINAING PRODUCTS MEDPALETT PHARMACEUTICALS AS (NO) 2003-05-15 WO claimed
US-6355684-B1 AQUEOUS BENZALKONIUM CHLORIDE, ECHINACEA AND ANTIMICROBIAL ISOLATES; VIRICIDES FOR PAPILLOMA, VARICELLA-ZOSTER, AND CYTOMEGALO VIRUSE; HIGH SPEED ANALGESIC; HEALING OF LESIONS; TOPICAL ADMINISTERING Squires, Meryl J. 2002-03-12 US claimed
US-5993881-A ANTHOCYANIN CONTAINING FRACTIONS ISOLATED FROM TART CHERRIES BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 1999-11-30 US claimed
US-5985636-A OF LIPIDS; USING EXTRACT OF TART CHERRIES BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) 1999-11-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303935-A1 Medicinal Composition MUSK, TNNC1, ACHE CD38 336/4885DPP4 3118/4885F2 1264/4885
US-20090082285-A1 Adiponectin expression promoter ADIPOR1, ADIPOR2, FABP4 CD38 72/4885DPP4 487/4885F2 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.